Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for Zolucatetide (FOG-001) in Desmoid tumors. The expected timing is based on the latest available company guidance and may change.
03/11/26:- FDA ODD granted to zolucatetide in desmoid tumors, following prior FTD; program progressing toward registrational trial. 08/13/26:- Phase 1/2 desmoid data will be presented at ESMO on October 23, 2026. More mature data and an FDA meeting are expected in Q4 2026; Phase 3 initiation is expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.